Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celgosivir (MDL 28,574A) in HIV-Infected Patients
NCT00002151Phase 2Completed
- Sponsor
- Hoechst Marion Roussel
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celgosivir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Hoechst Marion Roussel. Primary endpoints: Safety and Tolerability and Antiviral Efficacy. Status: completed.
02
Drugs
celgosivir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002151.